The FDA has approved Eli Lilly’s oral GLP-1 obesity drug orforglipron for adults with obesity or overweight plus weight-related conditions, marketed as Foundayo. Approval follows Lilly’s expected near-term rollout and adds a second oral option after Novo Nordisk’s December approval of Wegovy (semaglutide) pill, intensifying competition in the oral weight-loss market.